Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer

被引：7
作者：
Tamura, Tomohiro [1 ]
Kurishima, Koichi [2 ]
Nakazawa, Kensuke [1 ]
Ishikawa, Hiroichi [2 ]
Satoh, Hiroaki [3 ]
Hizawa, Nobuyuki [1 ]
机构：
[1] Univ Tsukuba, Div Resp Med, Fac Med, Mito, Ibaraki 3100015, Japan
[2] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan
[3] Univ Tsukuba, Div Resp Med, Mito Med Ctr, Mito, Ibaraki 3100015, Japan
来源：
ONCOLOGY LETTERS | 2015年 / 10卷 / 02期
关键词：
non-small cell lung cancer; stable disease; disease control rate; survival; RANDOMIZED PHASE-III; ERLOTINIB MAINTENANCE THERAPY; VINORELBINE PLUS CISPLATIN; 1ST-LINE TREATMENT; CLINICAL BENEFIT; PEMETREXED PLUS; OPEN-LABEL; CARBOPLATIN; TRIAL; EGFR;
D O I：
10.3892/ol.2015.3350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The present study aimed to evaluate the similar survival benefits of a good response [complete response or partial response (CR/PR)] and stable disease (SD) to chemotherapy in non-small cell lung cancer (NSCLC) patients in clinical practice. All 322 patients who were treated between 1999 and 2012 with first-line platinum-based chemotherapy were retrospectively analyzed. Tumor responses were classified according to the response evaluation criteria for solid tumors. A total of 67 (20.8%) patients experienced CR/PR and 165 (51.2%) achieved SD. There was no difference in progression-free survival between the patients with CR/PR and those with SD (P=0.347). There was also no difference between the two groups with regard to overall survival time (P=0.878). In multivariate analysis, disease-control (more than SD) was one of the favorable prognostic factors. In clinical practice, a survival benefit would be provided not only for the patients who have good response, but also for those with SD.
引用
收藏
页码：1135 / 1140
页数：6
相关论文
共 33 条
  • [1] Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
    Barlesi, F.
    Scherpereel, A.
    Gorbunova, V.
    Gervais, R.
    Vikstrom, A.
    Chouaid, C.
    Chella, A.
    Kim, J. H.
    Ahn, M. J.
    Reck, M.
    Pazzola, A.
    Kim, H. T.
    Aerts, J. G.
    Morando, C.
    Loundou, A.
    Groen, H. J. M.
    Rittmeyer, A.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (05) : 1044 - 1052
  • [2] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Szczesna, Aleksandra
    Juhasz, Erzsebet
    Esteban, Emilio
    Molinier, Olivier
    Brugger, Wolfram
    Melezinek, Ivan
    Klingelschmitt, Gaelle
    Klughammer, Barbara
    Giaccone, Giuseppe
    [J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
  • [3] Cesano A, 2000, INT J ONCOL, V17, P587
  • [4] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu, Tudor
    Brodowicz, Thomas
    Zielinski, Christoph
    Kim, Joo Hang
    Krzakowski, Maciej
    Laack, Eckart
    Wu, Yi-Long
    Bover, Isabel
    Begbie, Stephen
    Tzekova, Valentina
    Cucevic, Branka
    Pereira, Jose Rodrigues
    Yang, Sung Hyun
    Madhavan, Jayaprakash
    Sugarman, Katherine P.
    Peterson, Patrick
    John, William J.
    Krejcy, Kurt
    Belani, Chandra P.
    [J]. LANCET, 2009, 374 (9699) : 1432 - 1440
  • [5] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
    Coudert, B.
    Ciuleanu, T.
    Park, K.
    Wu, Y. -L.
    Giaccone, G.
    Brugger, W.
    Gopalakrishna, P.
    Cappuzzo, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (02) : 388 - 394
  • [6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [7] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Fidias, Panos M.
    Dakhil, Shaker R.
    Lyss, Alan P.
    Loesch, David M.
    Waterhouse, David M.
    Bromund, Jane L.
    Chen, Ruqin
    Hristova-Kazmierski, Maria
    Treat, Joseph
    Obasaju, Coleman K.
    Marciniak, Martin
    Gill, John
    Schiller, Joan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 591 - 598
  • [8] Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
    Fossella, F
    Pereira, JR
    von Pawel, J
    Pluzanska, A
    Gorbounova, V
    Kaukel, E
    Mattson, KV
    Ramlau, R
    Szczesna, A
    Fidias, P
    Millward, M
    Belani, CP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3016 - 3024
  • [9] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
  • [10] Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer
    He, Lijie
    Teng, Yuee
    Jin, Bo
    Zhao, Mingfang
    Yu, Ping
    Hu, Xuejun
    Zhang, Jingdong
    Li, Songbai
    Gao, Yaling
    Liu, Yunpeng
    [J]. BMC CANCER, 2010, 10
1234